{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/trigeminal-neuralgia/management/management/","result":{"pageContext":{"chapter":{"id":"5008bdc5-02f7-558d-9c72-fa0bd4f2c01a","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 30a3a062-de80-4b61-9015-a9669ab91081 --><h2>Scenario: Management of trigeminal neuralgia</h2><!-- end field 30a3a062-de80-4b61-9015-a9669ab91081 -->","summary":"Covers the management of people with trigeminal neuralgia in primary care.","htmlStringContent":"<!-- begin item f9cc493a-b827-413e-a64f-cb1660e999c8 --><!-- begin field 0489a45f-4dda-467f-ab52-acbd00880792 --><p>From age 18 years onwards.</p><!-- end field 0489a45f-4dda-467f-ab52-acbd00880792 --><!-- end item f9cc493a-b827-413e-a64f-cb1660e999c8 -->","topic":{"id":"b411a210-e8ef-56d4-8840-714bb3ca8b7d","topicId":"dd0f36c2-b31b-42ca-bc80-17ddb7e243ec","topicName":"Trigeminal neuralgia","slug":"trigeminal-neuralgia","lastRevised":"Last revised in January 2018","chapters":[{"id":"5a46b0ae-84bb-5e91-9f06-d82e7de90660","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6ebb1131-0f9c-5613-9b6d-c44044dc3d59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"04895c32-0679-538d-bd7f-566f3b1aca33","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"064b944d-9f86-5ad2-bdde-418e427a69cf","slug":"changes","fullItemName":"Changes"},{"id":"215b2ed2-a6ff-5053-b74a-72ca907fbb6f","slug":"update","fullItemName":"Update"}]},{"id":"0d57219c-f171-59f5-b932-8cabc9dd5049","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d78c8e6b-affd-55c5-8e55-1db5bbe57261","slug":"goals","fullItemName":"Goals"},{"id":"135b5ce1-adf5-5fa9-8d6a-a90e64183628","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2dd53a4e-0dcf-5797-90d1-ac0ae3a56a93","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8fd6b61-b1c3-538d-b032-872f1d3427c2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d867bfa-0e88-5dbe-85c4-50f28d24c9c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"38f48973-5497-53e5-a936-4b59cbd4b662","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff1b2d66-75ed-51c6-bfa9-fcc0ad6d6bac","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2e9fdd75-4a7e-56ad-8c9d-02ac90da26bd","slug":"definition","fullItemName":"Definition"},{"id":"4dc2aba7-3510-51d4-9aab-2596d348bd1a","slug":"causes","fullItemName":"Causes"},{"id":"6e2bbd60-dabb-5cdb-86d0-29bd0a23615b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7c45985c-eb6e-5f96-9d9b-44cc50b51476","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16848fcb-77c6-5043-9c84-eadffb6ff3aa","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7f1ea99-b3b5-5e53-952d-515327e12d83","slug":"complications","fullItemName":"Complications"}]},{"id":"5c22d7af-254a-51f1-a8b9-07efa299f48b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bbf28df3-9b64-5c32-85b5-26dc3c2cc0af","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"feea47e1-4766-5814-8cd9-3adf7df4600f","fullItemName":"Management","slug":"management","subChapters":[{"id":"5008bdc5-02f7-558d-9c72-fa0bd4f2c01a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ff7b11db-4087-5134-804a-f231a32cf2ce","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74b691ce-0764-54e6-a932-11f0755c3089","slug":"carbamazepine","fullItemName":"Carbamazepine"}]},{"id":"ae57d488-a470-558c-b5d7-81fb47f8fbad","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"90e907d0-34e8-53cc-a9f6-53b0de5c633c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c39bcb69-119d-5f65-927c-00c82813d6f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"614a98b5-320e-5735-b0f4-c72808b83068","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4c55bb70-6e39-5673-898f-4244d6e219e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8a3490-a3c6-565b-9f06-fc347a6c2eb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12e3df2a-fa39-57fa-b4ef-e222cd41fa5b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d1abb506-cecf-562c-84a9-1e2167e7129f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"feea47e1-4766-5814-8cd9-3adf7df4600f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"2228691a-40a7-5e05-a27f-c042864016e4","slug":"how-should-i-manage-a-person-with-trigeminal-neuralgia","fullItemName":"How should I manage a person with trigeminal neuralgia?","depth":3,"htmlHeader":"<!-- begin field 5b7437df-3a95-46db-bfa0-82fc08473043 --><h3>How should I manage a person with trigeminal neuralgia?</h3><!-- end field 5b7437df-3a95-46db-bfa0-82fc08473043 -->","summary":null,"htmlStringContent":"<!-- begin item 25727d45-51a5-46bc-91bb-9d051b4c2e11 --><!-- begin field 1eb94079-7ff8-4c81-8dfb-802c3eadbb2c --><ul><li><strong><strong>If there are</strong><strong> <a class=\"topic-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/diagnosis/diagnosis/\">red flag symptoms and signs</a> that may suggest a serious underlying cause, admit, or refer urgently for specialist assessment, using clinical judgement.</strong></strong></li><li><strong><strong>Assess the person for signs of depression. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a></strong></strong><strong><strong>.</strong></strong></li><li><strong>If there are no red flag symptoms and signs, </strong><strong>o</strong><strong>ffer the person carbamazepine</strong>.<ul><li>Start at 100 mg up to twice daily, and titrate in steps of 100 - 200 mg every two weeks, until pain is relieved.</li><li>In the majority of people a dosage of 200 mg three or four times a day is sufficient to prevent paroxysms of pain (maximum dosage 1,600 mg daily).</li><li>Modified release preparations may be useful at night if the person experiences breakthrough pain.</li><li>Once pain is in remission, the dosage should be gradually reduced to the lowest possible maintenance level, or the drug can be discontinued until a further attack occurs.</li><li>For further information on contraindications and cautions, adverse effects, drug interactions, and monitoring, with carbemazepine, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>If carbamazepine is contraindicated, ineffective, or not tolerated, seek specialist advice.</strong> <strong>Do <em>not </em>offer any other drug treatment unless advised to do so by a specialist. </strong>However, other treatments initiated by a specialist may be continued in primary care under a multidisciplinary care plan or a local shared-care agreement.</li><li><strong>Arrange early <a class=\"topic-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/management/management/#how-should-i-follow-up-a-person-with-trigeminal-neuralgia\">follow-up</a> to assess the progress made with dose titration, and the tolerability and effectiveness of the treatment. </strong>Use clinical judgement to decide how soon to follow-up the person.</li><li><strong>Advise the person:</strong><ul><li>On the importance of dosage titration, and the titration process, providing written information if possible. Explain that the treatment does not work immediately; it commonly takes weeks to titrate up to an effective dose.</li><li>On the possible <a class=\"topic-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/prescribing-information/carbamazepine/#adverse-effects\">adverse effects</a> associated with use of carbamazepine.</li><li>That a daily pain diary may be useful to help people learn to manage their pain.</li></ul></li><li><strong>Consider referring the person to a neurologist or specialist pain service if:</strong><ul><li>They have severe pain.</li><li>Their pain significantly limits their participation in daily activities (including self care, general tasks and demands, interpersonal interactions and relationships, mobility, and sleeping).</li></ul></li></ul><!-- end field 1eb94079-7ff8-4c81-8dfb-802c3eadbb2c --><!-- end item 25727d45-51a5-46bc-91bb-9d051b4c2e11 -->","subChapters":[{"id":"bfe1bbe6-b552-5e5e-985f-f5fcd87d0d48","slug":"basis-for-recommendation-bcf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0c3f3f4c-81af-48e5-b508-259d3d088610 --><h4>Basis for recommendation</h4><!-- end field 0c3f3f4c-81af-48e5-b508-259d3d088610 -->","summary":null,"htmlStringContent":"<!-- begin item bcfcf421-cc8e-4690-9c81-8a08be78eb35 --><!-- begin field 8522122d-b812-488c-ac1c-33576cb11e4a --><p>The recommendations on management of trigeminal neuralgia are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Neuropathic pain — pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">NICE, 2013</a>], and in a narrative review article published in the British Medical Journal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">Zakrzewska and Linskey, 2015</a>].</p><h5>Assessing for the presence of depression</h5><ul><li>The recommendation to assess people with trigeminal neuralgia for signs of depression recommendation is based on expert opinion in narrative review articles that trigeminal neuralgia is associated with an increased risk of depression and suicide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">Zakrzweska and Linskey, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">Zakrzewska and Linskey, 2015</a>].</li></ul><h5>Carbamazepine dosing</h5><ul><li>The information on carbemazepine dosing is taken from the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">BNF 72, 2016</a>].</li></ul><h5>Keeping a pain diary</h5><ul><li>The advice relating to keeping a pain diary is based on feedback from an expert reviewer of a previous version of this CKS topic. It was suggested that keeping a pain diary may help people to feel in control, to understand how their pain responds to medication, and when they may be experiencing a remission or relapse.</li></ul><h5>Early follow-up</h5><ul><li>In the expert opinion of the NICE guideline development group, an early clinical review is important to assess the progress made with titration as well as the effectiveness and tolerability of treatment. This allows any necessary treatment adjustments to be made promptly in order to ensure optimal pain control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">NICE, 2013</a>].</li><li>CKS recommends using clinical judgement to decide how soon to follow-up a person with neuropathic pain. This pragmatic advice is based on the fact that the urgency of a follow-up will depend on several factors including the cause of neuropathic pain, severity of pain, and the complexity of the titration process.</li></ul><!-- end field 8522122d-b812-488c-ac1c-33576cb11e4a --><!-- end item bcfcf421-cc8e-4690-9c81-8a08be78eb35 -->","subChapters":[]}]},{"id":"19ddb805-cab6-537e-9943-72966a93db56","slug":"how-should-i-follow-up-a-person-with-trigeminal-neuralgia","fullItemName":"How should I follow up a person with trigeminal neuralgia?","depth":3,"htmlHeader":"<!-- begin field 1a86a578-2680-4a47-90dd-b7b47e71abbc --><h3>How should I follow up a person with trigeminal neuralgia?</h3><!-- end field 1a86a578-2680-4a47-90dd-b7b47e71abbc -->","summary":null,"htmlStringContent":"<!-- begin item e56bafd3-f796-4130-af0a-791b906076ac --><!-- begin field 6bc4c0a0-aa96-4eca-a43a-00241d4b0a91 --><ul><li><strong>Assess the progress made with dose titration, and the tolerability and effectiveness of treatment.</strong><ul><li>Ask about the current dose of carbamazepine, any problems they have experienced titrating the dose upwards, and confirm that they understand the <a class=\"topic-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/management/management/#how-should-i-manage-a-person-with-trigeminal-neuralgia\">titration process</a>.</li><li>Ask about tolerability and <a class=\"topic-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/prescribing-information/carbamazepine/#adverse-effects\">adverse effects</a>, and whether these tend to improve or persist with time following each dose increase.</li><li>Assess the effectiveness of the treatment by asking about:<ul><li>The degree of pain.</li><li>The impact of the pain on participation in daily activities (including self care, general tasks and demands, interpersonal interactions and relationships, mobility, and sleeping).</li><li>Their mood (in particular, whether the person is depressed or anxious).</li></ul></li></ul></li><li><strong>If the treatment is poorly tolerated, </strong>use clinical judgement to decide whether to:<ul><li>Titrate the dose more slowly upwards (especially if adverse effects improve with time following each dose increase), <em>or</em></li><li>Refer to a specialist pain service or a neurologist.</li></ul></li><li><strong>If the treatment is reasonably well tolerated, </strong>continue titrating the dose upwards until either pain is well controlled or the maximum tolerated dose has been reached.<ul><li>If pain is poorly controlled on the maximum tolerated dose, refer to a specialist pain service or a neurologist.</li><li>If pain is well controlled, continue treatment. Consider gradually reducing the dose over time if the person remains pain-free for 1 month.</li></ul></li><li><strong>Consider referring the person to a specialist pain service or a </strong><strong>neurologist at any stage, if:</strong><ul><li>They have severe pain.</li><li>Their pain significantly limits their participation in daily activities (including self care, general tasks and demands, interpersonal interactions and relationships, mobility, and sleeping).</li><li>The person has atypical clinical features (for example burning pain between paroxysms, loss of sensation, or any abnormal neurological signs).</li></ul></li></ul><!-- end field 6bc4c0a0-aa96-4eca-a43a-00241d4b0a91 --><!-- end item e56bafd3-f796-4130-af0a-791b906076ac -->","subChapters":[{"id":"eedabd48-b57a-5b08-89b0-83b79fe6c7da","slug":"basis-for-recommendation-cec","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1ddf8a1e-67cf-4c0a-878b-a8a353c66996 --><h4>Basis for recommendation</h4><!-- end field 1ddf8a1e-67cf-4c0a-878b-a8a353c66996 -->","summary":null,"htmlStringContent":"<!-- begin item cecfbc4b-d9f5-4626-9863-fa8c3b6fa777 --><!-- begin field 8545ac77-139a-4739-8b0d-a1651d9a3f5f --><p>The recommendations on how to follow-up a person woth trigeminal neuralgia are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Neuropathic pain — pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">NICE, 2013</a>].</p><h5>Assessing progress made with dose titration, and tolerability, and effectiveness of treatment</h5><ul><li>In the expert opinion of the NICE guideline development group (GDG), assessing progress made with dose titration, the tolerability, and the effectiveness of the current treatment is important, to allow any necessary treatment adjustments to be made promptly in order to ensure optimal pain control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">NICE, 2013</a>].</li></ul><h5>Poorly tolerated treatment</h5><ul><li>CKS recommends using clinical judgement if treatment is poorly tolerated. This pragmatic advice is based on the fact that slower titration may reduce the risk of intolerable adverse effects for some people whilst others may need to be referred.</li></ul><h5>Reasonably well tolerated treatment</h5><ul><li>The recommendations to continue treatment if pain is well controlled and to consider gradually reducing the dose over time if the improvement is sustained is based on the expert opinion of the NICE GDG [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">NICE, 2013</a>].</li></ul><h5>Stopping treatment</h5><ul><li>CKS found no evidence on the recommended duration of treatment for trigeminal neuralgia. The opinions of expert reviewers of previous versions of this topic differed regarding the amount of time for which treatment should be tried before reducing or stopping medication. Considering this, alongside the information within the Summary of Product Characteristics for carbamazepine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">ABPI, 2015</a>], CKS has made a practical recommendation.</li></ul><h5>Referral</h5><ul><li>NICE recommends considering referral at any stage (including at initial presentation and at regular clinical reviews) if pain is severe; pain significantly limits daily activities and quality of life; their underlying health condition has deteriorated; or treatment is inappropriate, ineffective, or not tolerated, because [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">NICE, 2013</a>]:</li><li>Other criteria for referral are based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">Bennetto et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">Zakrzewska and Linskey, 2015</a>] and feedback from an expert reviewer of a previous version of this CKS topic.<ul><li>The diagnosis of trigeminal neuralgia should be reviewed if medical treatment fails.</li><li>Surgical options should be considered if pain control cannot be achieved, or drugs cause unacceptable adverse effects. This should be done at the earliest possible stage if medical treatment fails.</li><li>An MRI (magnetic resonance imaging) scan is indicated in younger people, those with atypical symptoms, people who do not respond to initial therapy, or anyone for whom neurosurgery is being considered. CKS recommends referral to a specialist for MRI assessment. CKS has used 40 years of age as a cut-off as trigeminal neuralgia is rare below this age.</li></ul></li></ul><!-- end field 8545ac77-139a-4739-8b0d-a1651d9a3f5f --><!-- end item cecfbc4b-d9f5-4626-9863-fa8c3b6fa777 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}